<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337687</url>
  </required_header>
  <id_info>
    <org_study_id>09-10-303</org_study_id>
    <nct_id>NCT01337687</nct_id>
  </id_info>
  <brief_title>Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders</brief_title>
  <acronym>INOT</acronym>
  <official_title>Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autism Spectrum Disorder (ASD) is a developmental disorder characterized by abnormalities in
      speech and communication, impaired social functioning and repetitive behaviors and restricted
      interests. Oxytocin (OT) is peptide that is known for its peripheral effects on facilitating
      uterine contractions and milk let-down; however, studies, mainly with rodents and non-human
      primates, has found that OT is involved in affiliative behaviors, including sexual behavior,
      mother-infant and adult-adult pair-bond formation, separation distress, and other aspects of
      social attachment. Moreover, OT is known to play an important role in repetitive behaviors
      and stress reactivity. Given that repetitive behaviors and deficits in social interaction are
      core symptom domains of autism, and that OT is involved in the regulation of repetitive and
      affiliative behaviors, it is believed that OT may play a role in the etiology of autism.
      Moreover, preliminary data obtained by Hollander and colleagues suggests that OT may be of
      value in treating core autism symptoms. Specifically, synthetic oxytocin administered via
      intravenous infusion to adults with autism spectrum disorders (ASD) produced significant
      reductions in repetitive behaviors and facilitated social cognition/memory in a double-blind,
      placebo-controlled cross-over laboratory challenge.

      Encouraged by these findings, the primary aim of this study is to investigate the safety and
      therapeutic efficacy of intranasal OT in treating repetitive behaviors and social
      functioning/cognitive deficits in adults with ASD. This research embraces a translational
      approach to develop a novel treatment for core ASD symptoms; given that there are currently
      no Food and Drug Administration (FDA) approved medication treatments for core ASD symptoms,
      this research addresses an important unmet need in the field. The goal of this study is to
      evaluate the safety and efficacy of repeated Intranasal Oxytocin Treatment
      (INOT)administration in adults with ASD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Improvement on the Clinical Global Impression-Improvement (CGI-I) Scale</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Rating Scale that utilizes direct observation, scales and patient report to inform clinical judgment. A form of CGI that targets social functioning will be used as the primary outcome measure. Semi-structured interview.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Obsessive- Compulsive Behavior Based on Yale Brown Obsessive Compulsive Scale (YBOCS)</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Clinician-Rated questionnaire measuring the time spent, distress,interference, resistance, and control in relation to obsessions and compulsions based on a 5 point scale ranging from 0-5 for each category with 0 being most desirable and 5 being least. Sub-scales are added and averaged to obtain total scores.
-scale range (total): 0 - 40 total, 0 - 7 subclinical, 8-15 mild, 16 - 23 moderate, 24 - 31 severe, 32 - 40 extreme
Questions are rated on a 5-point scale, 0-4, increasing in severity. Obsession Rating Subscale (5 questions, ranging from 0 - 20 total) and Compulsion Rating subscale (5 questions, ranging from 0 - 20 total) are totaled and added to obtain total scores.
-score interpretation: Higher overall scores reflect increasing symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Repetitive Behavior Based Repetitive Behavior Scale - Revised (RBS-R)</measure>
    <time_frame>Baseline, week 6</time_frame>
    <description>Subscale ranges: stereotypic behavior (0 - 27);self-injurious behavior (0 - 24); compulsive behavior (0 - 18); ritualistic/Sameness Behavior (0 - 36); restricted Interests (0 - 9).
Higher score in all subscales reflect increasing severity. Questions rate behaviors on a 4-point scale: 0 = does not occur; 1 = occurs, mild problem; 2 = occurs, moderate problem; 3 = occurs, severe problem. Subscale scores consist of sum of ratings within each question subset.
Lower order behaviors-- stereotypy and self-injury, higher order behaviors--compulsions, rituals /sameness, restricted interests.
Lower Order total range: 0-51, Higher Order total range: 0-63 Stereotypic behavior and Self-injurious behavior subscales were summed to create a total range for Lower Order behavior; and Compulsive behavior, ritualistic /sameness behavior, and restricted interests subscales were summed to create a total range for Higher Order behavior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Facial Emotion Recognition Based on Diagnostic Analysis of Nonverbal Accuracy - 2 (DANVA-2)</measure>
    <time_frame>baseline, week 6</time_frame>
    <description>A clinical tool measuring emotion recognition through facial expression, voice and posture.
Child faces 2 (range 0 - 100, higher values reflecting higher % of errors)
Adult faces 2 (range 0 - 100, higher values reflecting higher % of errors)
Child paralanguage 2 (range 0 - 100, higher values reflecting higher % of errors)
Adult paralanguage 2 (range 0 - 100, higher values reflecting higher % of errors) Errors are counted and organized by pre-determined affect and intensity. Subtests considered separately.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Autism Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Oxytocin</intervention_name>
    <description>Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.</description>
    <arm_group_label>Oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Female

          -  18 to 55 years old

          -  Meet Diagnostic and Statistical Manual-IV (DSM-IV), Autism Diagnostic Observation
             Schedule(ADOS), and Autism Diagnostic Interview-Revised (ADI-R) standards for Autism
             Spectrum Disorder or Aspergers Syndrome

          -  Have a high, normal or near normal Intelligent Quotient

          -  Speak and Understand English fluently

        Exclusion Criteria:

          -  Born prior to 35 weeks gestational age

          -  Any primary psychiatric diagnosis other than autism at the time of screening

          -  Medical history of neurological disease

          -  Medical history of known MRI/structural lesion of the brain

          -  Patients who are pregnant

          -  With a medical condition that might interfere with the conduct of the study, confound
             interpretation of study results or endanger their own well being

          -  With evidence or history of malignancy or any significant hematological, endocrine,
             cardiovascular, respiratory, renal, hepatic or gastrointestinal disease

          -  Taking psychoactive medications

          -  Who plan to initiate or change nonpharmacologic interventions during the study course

          -  Who are unable to tolerate venipuncture procedures for blood sampling
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Hollander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center/Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center, Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <results_first_submitted>March 17, 2016</results_first_submitted>
  <results_first_submitted_qc>February 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2020</results_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Eric Hollander</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>Autism Spectrum Disorders</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Hollander</keyword>
  <keyword>ASD</keyword>
  <keyword>Asperger Syndrome</keyword>
  <keyword>Asperger</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oxytocin</title>
          <description>Intranasal Oxytocin: Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxytocin</title>
          <description>Intranasal Oxytocin: Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" lower_limit="21" upper_limit="45"/>
                    <measurement group_id="B2" value="32.9" lower_limit="19" upper_limit="46"/>
                    <measurement group_id="B3" value="33.2" lower_limit="19.9" upper_limit="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Improvement on the Clinical Global Impression-Improvement (CGI-I) Scale</title>
        <description>Rating Scale that utilizes direct observation, scales and patient report to inform clinical judgment. A form of CGI that targets social functioning will be used as the primary outcome measure. Semi-structured interview.</description>
        <time_frame>6 Weeks</time_frame>
        <population>Participants rated as improved on the CGI-I scale</population>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Intranasal Oxytocin: Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement on the Clinical Global Impression-Improvement (CGI-I) Scale</title>
          <description>Rating Scale that utilizes direct observation, scales and patient report to inform clinical judgment. A form of CGI that targets social functioning will be used as the primary outcome measure. Semi-structured interview.</description>
          <population>Participants rated as improved on the CGI-I scale</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Obsessive- Compulsive Behavior Based on Yale Brown Obsessive Compulsive Scale (YBOCS)</title>
        <description>Clinician-Rated questionnaire measuring the time spent, distress,interference, resistance, and control in relation to obsessions and compulsions based on a 5 point scale ranging from 0-5 for each category with 0 being most desirable and 5 being least. Sub-scales are added and averaged to obtain total scores.
-scale range (total): 0 - 40 total, 0 - 7 subclinical, 8-15 mild, 16 - 23 moderate, 24 - 31 severe, 32 - 40 extreme
Questions are rated on a 5-point scale, 0-4, increasing in severity. Obsession Rating Subscale (5 questions, ranging from 0 - 20 total) and Compulsion Rating subscale (5 questions, ranging from 0 - 20 total) are totaled and added to obtain total scores.
-score interpretation: Higher overall scores reflect increasing symptom severity.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Intranasal Oxytocin: Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Obsessive- Compulsive Behavior Based on Yale Brown Obsessive Compulsive Scale (YBOCS)</title>
          <description>Clinician-Rated questionnaire measuring the time spent, distress,interference, resistance, and control in relation to obsessions and compulsions based on a 5 point scale ranging from 0-5 for each category with 0 being most desirable and 5 being least. Sub-scales are added and averaged to obtain total scores.
-scale range (total): 0 - 40 total, 0 - 7 subclinical, 8-15 mild, 16 - 23 moderate, 24 - 31 severe, 32 - 40 extreme
Questions are rated on a 5-point scale, 0-4, increasing in severity. Obsession Rating Subscale (5 questions, ranging from 0 - 20 total) and Compulsion Rating subscale (5 questions, ranging from 0 - 20 total) are totaled and added to obtain total scores.
-score interpretation: Higher overall scores reflect increasing symptom severity.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="3.9"/>
                    <measurement group_id="O2" value="10.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="2.9"/>
                    <measurement group_id="O2" value="8.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Repetitive Behavior Based Repetitive Behavior Scale - Revised (RBS-R)</title>
        <description>Subscale ranges: stereotypic behavior (0 - 27);self-injurious behavior (0 - 24); compulsive behavior (0 - 18); ritualistic/Sameness Behavior (0 - 36); restricted Interests (0 - 9).
Higher score in all subscales reflect increasing severity. Questions rate behaviors on a 4-point scale: 0 = does not occur; 1 = occurs, mild problem; 2 = occurs, moderate problem; 3 = occurs, severe problem. Subscale scores consist of sum of ratings within each question subset.
Lower order behaviors-- stereotypy and self-injury, higher order behaviors--compulsions, rituals /sameness, restricted interests.
Lower Order total range: 0-51, Higher Order total range: 0-63 Stereotypic behavior and Self-injurious behavior subscales were summed to create a total range for Lower Order behavior; and Compulsive behavior, ritualistic /sameness behavior, and restricted interests subscales were summed to create a total range for Higher Order behavior.</description>
        <time_frame>Baseline, week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Intranasal Oxytocin: Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Repetitive Behavior Based Repetitive Behavior Scale - Revised (RBS-R)</title>
          <description>Subscale ranges: stereotypic behavior (0 - 27);self-injurious behavior (0 - 24); compulsive behavior (0 - 18); ritualistic/Sameness Behavior (0 - 36); restricted Interests (0 - 9).
Higher score in all subscales reflect increasing severity. Questions rate behaviors on a 4-point scale: 0 = does not occur; 1 = occurs, mild problem; 2 = occurs, moderate problem; 3 = occurs, severe problem. Subscale scores consist of sum of ratings within each question subset.
Lower order behaviors-- stereotypy and self-injury, higher order behaviors--compulsions, rituals /sameness, restricted interests.
Lower Order total range: 0-51, Higher Order total range: 0-63 Stereotypic behavior and Self-injurious behavior subscales were summed to create a total range for Lower Order behavior; and Compulsive behavior, ritualistic /sameness behavior, and restricted interests subscales were summed to create a total range for Higher Order behavior.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Higher Order</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="10.6"/>
                    <measurement group_id="O2" value="20.0" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6:Higher Order</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="16.2"/>
                    <measurement group_id="O2" value="17.8" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Lower Order</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="4.6"/>
                    <measurement group_id="O2" value="4.9" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Lower Order</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.3"/>
                    <measurement group_id="O2" value="3.7" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Facial Emotion Recognition Based on Diagnostic Analysis of Nonverbal Accuracy - 2 (DANVA-2)</title>
        <description>A clinical tool measuring emotion recognition through facial expression, voice and posture.
Child faces 2 (range 0 - 100, higher values reflecting higher % of errors)
Adult faces 2 (range 0 - 100, higher values reflecting higher % of errors)
Child paralanguage 2 (range 0 - 100, higher values reflecting higher % of errors)
Adult paralanguage 2 (range 0 - 100, higher values reflecting higher % of errors) Errors are counted and organized by pre-determined affect and intensity. Subtests considered separately.</description>
        <time_frame>baseline, week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxytocin</title>
            <description>Intranasal Oxytocin: Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Facial Emotion Recognition Based on Diagnostic Analysis of Nonverbal Accuracy - 2 (DANVA-2)</title>
          <description>A clinical tool measuring emotion recognition through facial expression, voice and posture.
Child faces 2 (range 0 - 100, higher values reflecting higher % of errors)
Adult faces 2 (range 0 - 100, higher values reflecting higher % of errors)
Child paralanguage 2 (range 0 - 100, higher values reflecting higher % of errors)
Adult paralanguage 2 (range 0 - 100, higher values reflecting higher % of errors) Errors are counted and organized by pre-determined affect and intensity. Subtests considered separately.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DANVA -Face Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" spread="8.8"/>
                    <measurement group_id="O2" value="39.1" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DANVA- FACE Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" spread="6.4"/>
                    <measurement group_id="O2" value="37.4" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DANVA- Paralanguage Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="5.7"/>
                    <measurement group_id="O2" value="34.1" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DANVA- Paralanguage Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" spread="2.7"/>
                    <measurement group_id="O2" value="35.2" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oxytocin</title>
          <description>Intranasal Oxytocin: Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Forgetfulness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Casara Jean Ferretti</name_or_title>
      <organization>Montefiore Medical Center, Albert Einstein College of Medicine</organization>
      <phone>3472499694</phone>
      <email>cferrett@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

